Business
Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results
Net income of $0.8 millionAdjusted EBITDA1 of $1.3 millionPediatric Portfolio net revenue up 86% sequentiallyFirst quarterly sequential prescription increase
About this update from Aytu Biopharma, Inc.
[{"type":"text","content":"Net income of $0.8 millionAdjusted EBITDA1 of $1.3 millionPediatric Portfolio net revenue up 86% sequentiallyFirst quarterly sequential prescription increase for both ADHD and Pediatric portfolios since Q2 fiscal 2023$20.4 million cash balance at December 31, 2024Company to host conference call and webcast today, February 12, 2025, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / February 12, 2025 / Aytu BioPharma, Inc. (the \"Company\" or \"Aytu\") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for the fiscal 2025 second quarter.Q2 2025 HighlightsQuarterly sequential increase in prescriptions across both portfolios, led by 29% sequential growth from the Pediatric Portfolio.Pediatric Portfolio (antihistamine franchise and pediatric multivitamin franchise) net revenue increased 86% sequentially to $2.4 million versus $1.3 million in Q1 fiscal 2025, reflecting positive effects from recently implemented return-to-growth plan for the pediatric product line. Pediatric Portfolio net revenue increased 12% compared to Q2 fiscal 2024.ADHD Portfolio (Adzenys XR-ODT® and Cotempla XR-ODT®) net revenue increased 16% sequentially to $13.8 million versus $11.9 million in Q1 fiscal 2025 after adjusting for a one-time vendor agreement positively impacting Q1 fiscal 2025 net revenue by $3.3 million.Net income in Q2 fiscal 2025 was $0.8 million, or $0.13 net income per share basic and $0.26 net loss per share diluted, compared to a net loss of $0.2 million, or $0.04 net loss per share basic and diluted in Q2 fiscal 2024.Adjusted EBITDA was $1.3 million in Q2 fiscal 2025 compared to $5.5 million in Q2 fiscal 2024.Cash and cash equivalents were $20.4 million at December 31, 2024, compared to $20.1 million at September 30, 2024.Management Discussion\"We successfully returned both our ADHD and Pediatric portfolios to positive sequential prescription growth during the second quarter, the first such occurrence in which both portfolios exhibited sequential prescription growth since late-2022,\" noted Josh Disbrow, Chief Executive Officer of Aytu. \"Our entire commercial team has done a great job navigating the various dynamics of the macro landscapes for our addressable markets. In the quarter, our sales team employed a focused and efficient promotional appr...